Announcement • Apr 25
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Presents Four Innovative Drug Research Abstracts At The 2026 AACR Meeting
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. made this announcement on a voluntary basis. Four innovative drug research abstracts of the Company have been presented in the form of posters at the 2026 Annual Meeting of the American Association for Cancer Research (AACR), held at the San Diego Convention Center, California, the United States from April 17 to 22, 2026. These selected achievements further validate the Company’s research and development capabilities and innovation strength. Details of the poster presentations are set out below: 1. CTLA-4/SIRPa BIFUNCTIONAL FUSION PROTEIN: HX044 HX044 is a globally innovative CTLA-4/SIRPa bifunctional fusion protein and an next-generation CTLA-4 targeted therapy. By simultaneously targeting CTLA-4 and CD47, it enhances the depletion of regulatory T-cells in the tumor microenvironment, thereby reducing tumor immunosuppression and strengthening anti-tumor activity. It is mainly developed for solid tumors resistant to PD-1/ICI therapy, forming a synergistic and complementary tumor immunology pipeline with HX009 developed by the Company. Abstract Title: Non-Clinical PK and PD Modeling to Assess the Therapeutic Window of HX044, a Novel CTLA4xCD47 BsAb, as Comparison with Ipilimumab. Summary & Conclusions: 1. Different human tumors indeed have higher %CD47+/CTLA4+ Treg than peripheral, and these TIL-Treg cells have higher levels of CTLA41, enabling preferential targeting of TIL-Treg by HX044 (vs Ipi). 2. Considering increased efficacy by lowering efficacious dose levels, and minimal change in irAE dose levels (vs. Ipi), HX044 exhibited widened TW (could be around 4x). These positive preclinical data have laid a solid foundation for the clinical development of HX044, which is currently in Phase I clinical stage. 2. BISPECIFIC ANTIBODY-DRUG CONJUGATE (BsAbADC): HX116 HX116 is a potential first-in-class bispecific antibody-drug conjugate (BsAbADC) independently developed by the Company, targeting PD-(L)1 6VEGF. It incorporates additional mechanisms of action (such as direct tumor killing and anti-tumor immunity enhanced by immunogenic cell death) to boost anti-tumor activity and has significant market potential. In preclinical studies, HX116 demonstrated superior activity over its parental BsAb. Abstract Title: Explore a Novel Multi-Modal PD-L1xVEGF-ADCs (HX116) for Potential Enhanced Potency For Solid Tumor Treatments. Summary & Conclusions: 1. HX116 binds and internalizes to PD-L1+ cells, which are both enhanced in the presence of VEGF (abundant in tumors). 2. HX116 internalizes efficiently into PD-L1+ tumor organoids and induced comparable cytotoxicity as SGN-PDL1V, the lead PD-L1-ADC in clinics; This observation may hint more specific targeting tumor (3D tumor organoid vs. 2D cells) or less off-tumor toxicity than SGN-PDL1V. 3. All modalities of HX116 contributed to anti-tumor activity, superior to parental BsAb. 3. PD-L1 TARGETED ANTIBODY-DRUG CONJUGATE: HX112 HX112 is a novel PD-L1 targeted antibody-drug conjugate (ADC) independently developed by the Company, intended for the treatment of pan-solid tumors. Abstract Title: A Novel Multi-Modal PD-L1-ADC Could be a Potential Candidate Treatment for Pan-Solid Tumors with Enhanced Tumor-Specificity. Summary & Conclusions: 1. Efficient internalization in 3D tumor organoids: In 2D cells, most PD-L1 ADCs show weak endocytosis and cytotoxicity, with the exception of SGN-PDL1V. In 3D organoids, HX112 exhibits internalization capacity and cytotoxicity comparable to SGN-PDL1V. Given that 3D tumor organoids more closely resemble the actual tumor phenotype, HX112 may have greater tumor specificity than SGN-PDL1V. 2. Potential to avoid TME-cleavable linker design and reduce off-target toxicity: If HX112 can be efficiently internalized into tumor cells, it may not require a tumor microenvironment (TME)-cleavable linker, thereby avoiding the potential side effects associated with such a mechanism. 4. 3D TUMOR ORGANOID ADC EVALUATION SYSTEM This study introduces an innovative preclinical ADC evaluation platform established by the Company, validating that 3D tumor organoids are more predictive of in vivo anti-tumor efficacy than 2D cell cultures. Abstract Title: 3D-Tumor Organoid, over 2D-Cell, Is More Predictive of In Vivo Anti-Cancer Pharmacology in Assessing ADC Candidates. Summary & Conclusions: 1. Despite similar high-affinity binding to PD-L1 or PD-L1+ 2D cell lines, antibodies targeting different epitopes, exhibited great differences in internalization, which may result in significant difference for the corresponding ADCs in cytotoxicity. 2. 3D-tumor organoid are more predictive of in vivo anti-tumor pharmacology over 2D-cell cultures, supporting a more powerful streamlined assessment of preclinical ADC candidates using tumor organoid, in addition to 2D cell cultures. The Company will continue to advance the research and development of its innovative drug pipeline, committed to providing more effective and safer treatment options for cancer patients.
